U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula CH4N2O
Molecular Weight 60.0553
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Urea

SMILES

NC(N)=O

InChI

InChIKey=XSQUKJJJFZCRTK-UHFFFAOYSA-N
InChI=1S/CH4N2O/c2-1(3)4/h(H4,2,3,4)

HIDE SMILES / InChI

Molecular Formula CH4N2O
Molecular Weight 60.0553
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Pastaron (Urea) is a waste product of many living organisms, and is the major organic component of human urine. It is a very important starting material in a number of chemical syntheses, and is used on an industrial scale for the manufacture of fertilizers, pharmaceuticals, and resins. Urea is an osmotic diuretic similar to mannitol but more irritant. Applied topically, urea promotes hydration of keratin and mild keratolysis in dry skin. It increases water uptake by the stratum corneum and has an antipruritic effect. Pastaron is used to soften rough or dry skin caused by skin conditions such as eczema, psoriasis, keratosis, and others.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
UREAPHIL

Approved Use

Pastaron is used topically to treat hyperkeratotic conditions such as dry, rough skin, ichthyosis (rough, thick, and scaly skin), skin cracks and fissures, dermatitis (inflammation of skin), eczema, psoriasis, keratosis (rough, scaly patch on skin) and calluses (hard and thickened area on skin, especially hands or feet).

Launch Date

1966
Palliative
UREAPHIL

Approved Use

Pastaron is used topically to treat hyperkeratotic conditions such as dry, rough skin, ichthyosis (rough, thick, and scaly skin), skin cracks and fissures, dermatitis (inflammation of skin), eczema, psoriasis, keratosis (rough, scaly patch on skin) and calluses (hard and thickened area on skin, especially hands or feet).

Launch Date

1966
Palliative
UREAPHIL

Approved Use

Pastaron is used topically to treat hyperkeratotic conditions such as dry, rough skin, ichthyosis (rough, thick, and scaly skin), skin cracks and fissures, dermatitis (inflammation of skin), eczema, psoriasis, keratosis (rough, scaly patch on skin) and calluses (hard and thickened area on skin, especially hands or feet).

Launch Date

1966
PubMed

PubMed

TitleDatePubMed
Selective inactivation of guanine-nucleotide-binding regulatory protein (G-protein) alpha and betagamma subunits by urea.
2001-03-01
Molecular characterization of a novel urea transporter from kidney inner medullary collecting ducts.
2001-03
Urea sensitizes mIMCD3 cells to heat shock-induced apoptosis: protection by NaCl.
2001-03
The impact of urea on viscosity of hydroxethyl cellulose and observed mobility of deoxyribonucleic acids.
2001-03
Evaluation of a novel vitamin E coated cellulosic membrane hollow fiber dialyzer.
2001-02-24
A Gaussian statistical mechanical model for the equilibrium thermodynamics of barnase folding.
2001-02-23
Predicting the kinetics of peptide-antibody interactions using a multivariate experimental design of sequence and chemical space.
2001-02-17
[Clinical value of urinary biochemical parameters].
2001-02-15
Do urea and sodium chloride together increase the efficacy of moisturisers for atopic dermatitis Skin? A comparative, double-blind and randomised study.
2001-02-15
Cisplatin pharmacokinetics and its nephrotoxicity in diabetic rabbits.
2001-02-15
Determination of macromolecular folding and structure by synchrotron x-ray radiolysis techniques.
2001-02-15
Structural stabilization of [2Fe-2S] ferredoxin from Halobacterium salinarum.
2001-02-06
The combination ace-inhibitors plus canreonate in patients with anterior myocardial infarction: safety and tolerability study.
2001-02
Physiological and molecular characterization of urea transport by the gills of the Lake Magadi tilapia (Alcolapia grahami).
2001-02
Renal replacement therapy and secondary hyperoxalemia in chronic renal failure.
2001-02
Protein-bound uremic solutes: the forgotten toxins.
2001-02
DNA damage of lymphocytes in experimental chronic renal failure: beneficial effects of losartan.
2001-02
Carbamoylation of amino acids and proteins in uremia.
2001-02
Role of nitric oxide in the synthesis of guanidinosuccinic acid, an activator of the N-methyl-D-aspartate receptor.
2001-02
Increased reduction of dimethylarginines and lowered interdialytic blood pressure by the use of biocompatible membranes.
2001-02
Urea-induced inducible nitric oxide synthase inhibition and macrophage proliferation.
2001-02
How to determine ionic dialysance for the online assessment of delivered dialysis dose.
2001-02
Changing hemodialysis thresholds for optimal survival.
2001-02
Functional glucocorticoid receptors in the mesonephros of the ovine fetus.
2001-02
Urea is a product of ureidoglycolate degradation in chickpea. Purification and characterization of the ureidoglycolate urea-lyase.
2001-02
Quantification of benzoic, phenylacetic, and phenylbutyric acids from filter-paper blood spots by gas chromatography--mass spectrometry with stable isotope dilution.
2001-02
Plasma transforming growth factor beta(1) and platelet activation: implications for studies in transplant recipients.
2001-02
Localization of the RAR interaction domain of cellular retinoic acid binding protein-II.
2001-01-26
Intestinal fatty acid binding protein: the folding mechanism as determined by NMR studies.
2001-01-23
Mapping the energy surface for the folding reaction of the coiled-coil peptide GCN4-p1.
2001-01-23
Canine parvovirus capsid assembly and differences in mammalian and insect cells.
2001-01-20
Synthesis and comparative molecular field analysis (CoMFA) of symmetric and nonsymmetric cyclic sulfamide HIV-1 protease inhibitors.
2001-01-18
Effect of some enhancers on the permeation of haloperidol through rat skin in vitro.
2001-01-16
N-(Hydroxyaminocarbonyl)phenylalanine: a novel class of inhibitor for carboxypeptidase A.
2001-01
An approach to the sensitivity of temperature-gradient gel electrophoresis in the detection of clonally expanded T-cells in cutaneous T-cell lymphoma.
2001-01
Evaluation of serological markers for the immunodiagnosis of acute acquired toxoplasmosis.
2001-01
Antipseudomonal antibiotics.
2001-01
Leaf ureide degradation and N(2) fixation tolerance to water deficit in soybean.
2001-01
Glucose appearance rate after the ingestion of galactose.
2001-01
Evaluation of fish models of soluble epoxide hydrolase inhibition.
2001-01
Effect of denaturants on the emulsifying activity of proteins.
2001-01
Improvement of metabolic performance of cultured hepatocytes by high oxygen tension in the atmosphere.
2001-01
The capsaicin analogue SDZ249-665 attenuates the hyper-reflexia and referred hyperalgesia associated with inflammation of the rat urinary bladder.
2001-01
In search of susceptibility genes for type 2 diabetes in West Africa: the design and results of the first phase of the AADM study.
2001-01
Influence of nutritional factors and hemodialysis adequacy on the survival of 1,610 French patients.
2001-01
The complexity of simplicity.
2001
Investigating the reaction of a novel silica capillary coating compound with proteins/peptides by matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry.
2001
Diagnostic accuracy of (13)C-urea breath test in the diagnosis of Helicobacter pylori infection in patients with partial gastric resection due to peptic ulcer disease: a prospective multicenter study.
2001
High density culturing of porcine hepatocytes immobilized on nonwoven polyurethane-based biomatrices.
2001
Characterization of nuclear factors binding to AT-rich element in the rat p53 promoter.
2001
Patents

Sample Use Guides

Applied to the affected area one or several times a day.
Route of Administration: Topical
Endometrial explants were cultured and treated with 0, 4, 8, 12, 16 mM of urea. Relative FGF2 gene expression was less in explants treated with a greater concentration of urea (16mM) when compared with lesser concentrations. Expression of HSPA1A, IGFBP3, and SERPINA14 genes was greater in explants exposed to lesser concentrations of urea (4mM). Greater concentrations of urea have negative effects on some endometrial gene expression, while moderate concentrations have positive effects.
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:35:12 GMT 2025
Edited
by admin
on Mon Mar 31 17:35:12 GMT 2025
Record UNII
8W8T17847W
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Urea
EP   FCC   HPUS   HSDB   II   INCI   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD  
INCI  
Official Name English
FLUOROURACIL IMPURITY G [EP IMPURITY]
Preferred Name English
UREA [USP IMPURITY]
Common Name English
UREA [MART.]
Common Name English
INS NO.927A
Code English
CALMURID HC COMPONENT UREA
Common Name English
UREA [USP MONOGRAPH]
Common Name English
U-CORT COMPONENT UREA
Common Name English
AZODICARBOXYLIC ACID-DIAMIDE
Common Name English
UREA [II]
Common Name English
UREA [EP MONOGRAPH]
Common Name English
UREA [VANDF]
Common Name English
AZOBISFORMAMIDE
Systematic Name English
INS-927A
Code English
UREA [ORANGE BOOK]
Common Name English
CARMOL HC COMPONENT UREA
Common Name English
ALLANTOIN IMPURITY B [EP IMPURITY]
Common Name English
UREA [FCC]
Common Name English
ALPHADERM COMPONENT UREA
Common Name English
UREA [HSDB]
Common Name English
E-927A
Code English
UREA [MI]
Common Name English
UREA [USP-RS]
Common Name English
UREA [JAN]
Common Name English
UREA [HPUS]
Common Name English
NSC-34375
Code English
Carbamide
Common Name English
Urea [WHO-DD]
Common Name English
Classification Tree Code System Code
LOINC 39781-0
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 12266-3
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 25550-5
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 57392-3
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 12268-9
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 3090-8
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 39779-4
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 40406-1
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
CODEX ALIMENTARIUS (GSFA) E-927A
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 47708-3
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 22664-7
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 12978-3
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 12977-5
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 20978-3
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
WHO-VATC QB05BC02
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 12974-2
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
FDA ORPHAN DRUG 192204
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 72926-9
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 77136-0
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 56996-2
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
WHO-ATC D02AE51
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 58885-5
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 12975-9
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 20977-5
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 58991-1
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 22738-9
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 20979-1
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
NCI_THESAURUS C49187
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
FDA ORPHAN DRUG 346211
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 47798-4
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 45302-7
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 56995-4
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 12973-4
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
WHO-VATC QD02AE51
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 25998-6
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
EPA PESTICIDE CODE 85702
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 39780-2
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 59786-4
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 58831-9
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 47707-5
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 39783-6
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 42571-0
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 56997-0
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 12966-8
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 48999-7
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 12981-7
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
DSLD 3894 (Number of products:6)
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
JECFA EVALUATION E-927A
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
CFR 21 CFR 310.538
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 49802-2
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 12965-0
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 57388-1
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 3091-6
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 3092-4
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 47709-1
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 12971-8
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 57389-9
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 40405-3
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 32556-3
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
WHO-ATC D02AE01
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
WHO-VATC QD02AE01
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 23786-7
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
CFR 21 CFR 184.1923
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 57385-7
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 74082-9
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 12979-1
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 63481-6
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
WHO-ATC B05BC02
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 12267-1
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 72927-7
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 12972-6
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 48117-6
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 12970-0
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 55609-2
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 59168-5
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 22700-9
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 12964-3
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 75364-0
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 12969-2
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
CFR 21 CFR 310.527
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 53137-6
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 40487-1
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 25549-7
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 25999-4
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 12968-4
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
WHO-ESSENTIAL MEDICINES LIST 13.4
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 72903-8
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
LOINC 12976-7
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
Code System Code Type Description
EPA CompTox
DTXSID4021426
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
PRIMARY
RXCUI
11002
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
PRIMARY RxNorm
DRUG BANK
DB03904
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
PRIMARY
RS_ITEM_NUM
1706698
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
PRIMARY
SMS_ID
100000091977
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
PRIMARY
MESH
D014508
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
PRIMARY
EVMPD
SUB15662MIG
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
PRIMARY
WIKIPEDIA
Urea-containing cream
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
PRIMARY
CHEBI
16199
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
PRIMARY
ChEMBL
CHEMBL985
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
PRIMARY
WIKIPEDIA
UREA
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
PRIMARY
PUBCHEM
1176
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
PRIMARY
DAILYMED
8W8T17847W
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
PRIMARY
NCI_THESAURUS
C29531
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
PRIMARY
CAS
57-13-6
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
PRIMARY
NSC
34375
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
PRIMARY
HSDB
163
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
PRIMARY
ECHA (EC/EINECS)
200-315-5
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
PRIMARY
DRUG CENTRAL
4264
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
PRIMARY
FDA UNII
8W8T17847W
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
PRIMARY
MERCK INDEX
m11322
Created by admin on Mon Mar 31 17:35:12 GMT 2025 , Edited by admin on Mon Mar 31 17:35:12 GMT 2025
PRIMARY Merck Index
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (TLC)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY